Afrezza (MNKD) - Margin resik

Logo grafis Afrezza (MNKD)

MannKind Corporation is expanding its presence in the endocrinology market through the innovative pulmonary delivery of Afrezza. The profit margin confirms the effectiveness of this strategy, where -18.10 reflects the current value of the metric. High brand authority among physicians ensures patient trust. A stable staff of specialized researchers and the targeted hiring of commercial experts guarantee sustainable business growth.

Margin dodolan resik Afrezza (MNKD): kanggo periode 04.07.2022 - 20.11.2026

Rincian metrik komprehensif lan analitis MannKind Corp. (MNKD)

- indikator kapitalisasi pasar:
Ringkesan analisis perusahaan:MannKind, MNKD
Produk asil prodhuksi MannKind Corp

For MannKind Corporation (MNKD), whose revenues depend on the commercialization of Afrezza and Tyvaso DPI royalties, the net profit margin reflects the efficiency of innovation monetization. This indicator measures the share of final profit in every dollar of revenue, allowing the investor to assess the deviation of current profitability from historical values and determine the business life cycle stage.

Karo sapa MannKind Corporation saingan

HLN: Margin dodolan resik|Rentabilitas dodolan resik KVUE|Margin resik veronapharma.com|Rentabilitas dodolan resik MENS (Jyong Biotech Corp)|Margin resik Ligand (LGND)|Margin dodolan resik amneal.com (AMRX)|Margin dodolan resik PRGO (perrigo.com)|Alvotech SA (ALVO) - Margin resik|Liquidia Inc. - Margin dodolan resik|Tingkat bathi miturut bathi resik Galapagos Corp (GLPG)|ANI Pharmaceuticals (ANIP) - Margin resik|amphastar.com (AMPH) - Margin dodolan resik|PCRX (Pacira Pharmaceuticals) - Margin dodolan resik|Rentabilitas dodolan miturut bathi resik ARS Pharmaceuticals, Inc. (SPRY)|Margin dodolan resik TBPH|AQST (Aquestive Therapeutics) - Tingkat bathi resik|scPharmaceuticals, Inc. - Rentabilitas dodolan miturut bathi resik|Tingkat bathi resik TECX|tonixpharma.com - Margin dodolan resik|Tingkat bathi resik SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Margin resik|Rentabilitas dodolan miturut bathi resik BioHarvest|Rentabilitas dodolan miturut bathi resik EXOZ|Rentabilitas dodolan miturut bathi resik Oramed Pharmaceuticals (ORMP)|Rentabilitas dodolan miturut bathi resik ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Rentabilitas dodolan resik|Margin dodolan resik ABVC (ABVC BioPharma Inc)|CPIX - Rentabilitas dodolan miturut bathi resik|Quantum BioPharma Corp - Margin dodolan resik|FGEN (fibrogen.com) - Rentabilitas dodolan resik|TELO (Telomir Pharmaceuticals) - Rentabilitas dodolan miturut bathi resik|Rani Therapeutics Holdings - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik SNYR|Margin resik rallybio.com RLYB|Margin dodolan resik LEXX|PULM (Pulmatrix, Inc.) - Tingkat bathi resik|Pheton Holdings - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Aptorum Group Limited APM|LYRA: Rentabilitas dodolan miturut bathi resik|IBO: Margin resik|TNFA: Margin dodolan resik|YCBD: Rentabilitas resik perusahaan|Margin resik PainReform Ltd|CYTO (altamiratherapeutics.com) - Rentabilitas resik perusahaan|Margin dodolan resik LIPO|OPTN - Margin resik|Margin resik pieris.com PIRS|Tingkat bathi resik PROC|PTPI - Margin resik|Qilian International Holding (QLI) - Rentabilitas dodolan miturut bathi resik|SLRN: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik TFF Pharma